Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype

Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype

GAD-alum given into lymph nodes to Type 1 diabetes (T1D) patients participating in a multicenter, randomized, placebo-controlled double-blind study seemed to have a positive effect for patients with DR3DQ2 haplotype, who showed better preservation of C-peptide than the placebo group. Here we compare...

Full description

Bibliographic Details
Main Authors: Sara Puente-Marin, Fabrícia Dietrich, Peter Achenbach, Hugo Barcenilla, Johnny Ludvigsson, Rosaura Casas
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Immunology
Subjects:
immunotherapy
autoantigen
GAD-alum
type 1 diabetes
DR3DQ2 haplotype
intra-lymphatic treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1112570/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1112570/full

Similar Items